Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving blood clotting factor
Reexamination Certificate
2007-11-13
2007-11-13
Saucier, Sandra E. (Department: 1651)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving blood clotting factor
C436S069000
Reexamination Certificate
active
11127540
ABSTRACT:
Provided are compositions and methods for accurate determination of the concentration of anticoagulant in a sample such as a blood or plasma sample. The compositions can contain a Factor X compound and Factor V compound, and additional components as well. Methods for performing the assay include one-step methods in which a sample is added to a coagulation assay composition, and time is monitored from the point of adding the sample and coagulation assay composition to an endpoint, such as clot formation.
REFERENCES:
patent: 4234682 (1980-11-01), Bartl et al.
patent: 4851336 (1989-07-01), Yin
patent: 4946775 (1990-08-01), Yin
patent: 5110727 (1992-05-01), Oberhardt
patent: 5192689 (1993-03-01), Hemker et al.
patent: 5308755 (1994-05-01), Nesheim et al.
patent: 5409959 (1995-04-01), Hwang et al.
patent: 5547850 (1996-08-01), Nowak et al.
patent: 5547944 (1996-08-01), Mascellani et al.
patent: 5576304 (1996-11-01), Kakkar et al.
patent: 5702912 (1997-12-01), Hemker et al.
patent: 6114135 (2000-09-01), Goldstein
patent: 6140062 (2000-10-01), Wagenvoord
patent: 6150114 (2000-11-01), Feigen et al.
patent: 6156734 (2000-12-01), Grinnell et al.
patent: 6194394 (2001-02-01), Hawkins
patent: 6528273 (2003-03-01), Hawkins
patent: 6566140 (2003-05-01), Mann et al.
patent: 6630989 (2003-10-01), Caputo et al.
patent: 6645768 (2003-11-01), Tejidor et al.
patent: 6699718 (2004-03-01), Bruegger
patent: 2003/0104508 (2003-06-01), Gempeter
patent: WO 01/44493 (2001-06-01), None
Nesheim et al., “Isolation and Characterization of Single Chain Bovine Factor V”, JBC (1979), 254 (2), 508-17.
Barton et al., “Reactions of activated factor X-phosphatide mixtures in vitro and in vivo,”J. Lipid Res.11:87-95 (1970).
Bell et al.,Nature, 174:880 (1954).
Biggs et al,Human Blood Coagulation and Its Disorders, 3rd edition (1962), pp. 54-66.
Biggs,Human Blood Coagulation, Haemostasis and Thrombosis, (1972), pp. 592-601.
Campbell, PJ et al., “HEPTEST: a suitable method for monitoring heparin during pregnancy,”Clin Lab Haematol, Jun. 21:193-9 (1999).
Dahlback, “Human coagulation factor V purification and thrombin-catalyzed activation”J. Clin. Invest., 66:583-91 (1980).
Harenberg, J. et al., “Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives,”Haemostasis, 19:13-20 (1989).
International Search Report dated May 19, 2006 issued on International Application No. PCT/US2005/16249.
Kane et al., “Purification and characterization of human coagulation factor V,”J. Biol. Chem., 256:1002-1007 (1980).
Kristensen, HI et al., “Effect of tissue factor pathway inhibitor (TFPI) in the HEPTEST assay and in an amidolytic anti factor Xa assay for LMW heparin,”Thromb Haemost, Sep. 7;68(3):310-4 (1992).
Martinez et al., Deciphering the plasma membrane hallmarks of apoptotic cells: Phosphatidylserine transverse redistribution and calcium entry,BMC Cell Biology, 2:20 (2001).
Papahodjoupolus et al.,Proc. Soc. Exp. Biol. Med., 111:412 (1962).
Smirnov et al., “A chimeric protein C containing the prothrombin Gla domain exhibits increased anticoagulant activity and altered phospholipid specificity,”J Biol Chem., 273:9031-9040 (1998).
Welsby, IJ. et al., “Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass,”J Clin Monit Comput., Jul. 17(5):287-92 (2002).
Yin et al, “Bovine thrombin and activated factor X. Separation and purification,”J. Biol. Chem, 243:112-117 (1968).
Yin et al, “Plasma heparin: a unique, practical, submicrogram-sensitive assay,”J. Lab. Clin. Med., 81:298 (1973).
Zwaal, RF. Et al., “Lipid-protein interactions in blood coagulation,”Biochim Biophys Acta., Nov. 10;1376(3):433-53 (1998).
Hendrice, C. et al., “Effects of aprotinin on blood loss, heparin monitoring tests, and heparin doses in patients undergoing coronary artery bypass”,Journal of Cardiothoracic&Vascular Anesthesia, 9(3):245-9, 1995. (Abstract only).
Hellstern, Peter et al., “Heparin Monitoring during Cardiopulmonary bypass Surgery using the One-Step Point-of-Care Whole Blood Anti-Factor-Xa Clotting Assay Heptest-POC-HI™”,Journal of Extracorporeal Circulation Technology2007 (publication pending).
Hansen, Roland et al., “A quick Anti-Xa-Activity-Based Whole Blood Coagulation Assay for Monitoring Unfractionated Heparin During Cardiopulmonary Bypass: A Pilot Investigation”,Anesth Analg., 91:533-8, 2000.
Kristensen et al., “A Fast Amidolytic Anti-Factore Xa Assay Not Influenced by Aprotinin for Monitoring of Heparin During Cardio-Pulmonary By-Pass Operation”, Abstracts of XIVth Congress of the International Society on Thrombosis and Haemostasis, New York, New York, USA, Jul. 4-9, 1993, published inThrombosis and Haemostasis—Journal of the International Society on Thrombosis and Haemostasis, 69(6):538-1455, Jun. 30, 1993. ISSN: 0340-6245. Abstract only.
LandOfFree
Compositions, kit and one-step method for monitoring... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions, kit and one-step method for monitoring..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions, kit and one-step method for monitoring... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3805515